bmiMD vs Cost Plus Drugs
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Cost Plus Drugs
Best for: coverage in all 50 states, which most of the register will not confirm
Visit Cost Plus Drugs →Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, bmiMD opens cheaper — $99/mo against $279, and bmiMD finishes ahead, 9.1 to 6.5. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
bmiMD
Ladder by plan length: 12 mo $99/mo (Total $1,188.00), 6 mo $109/mo, 3 mo $119/mo, 1 mo $129/mo. 'Same price at every dose'; provider visit + free shipping included. Verified 2026-07-14 at bmimd.com/personalized-glp-1/ and /semaglutide-injection/.
Ladder by plan length: 12 mo $139/mo (Total $1,668.00), 6 mo $149/mo, 3 mo $159/mo, 1 mo $179/mo. Same flat-dose model. Verified 2026-07-14 at bmimd.com/tirzepatide-injection/.
Strike-through pricing shown: $151.20 -> $99/mo (12-mo) up to $199.80 -> $129/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-microdose/.
Strike-through pricing shown: $250.20 -> $139/mo (12-mo) up to $299.70 -> $179/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-gip-microdose/.
Cost Plus Drugs
What’s included
bmiMD
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Cost Plus Drugs
Inclusions not disclosed.
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
bmiMD
9.1/10
Cost Plus Drugs
6.5/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | bmiMD | Cost Plus Drugs |
|---|---|---|
| Starting Price | ✓$99/mo | $279/mo |
| Features | 2 features | ✓5 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About bmiMD
bmiMD is a medical weight loss clinic that prescribes GLP-1 medications through telehealth.
Read our full bmiMD review →About Cost Plus Drugs
Cost Plus Drugs is Mark Cuban's transparent-pricing online pharmacy. It sells branded Ozempic at the wholesale acquisition cost plus a 15% markup and a flat $5 pharmacy fee, a margin formula it discloses publicly. There is no telehealth intake; this is pharmacy fulfillment only, shipping to all 50 states. Telehealth platforms that route brand-name semaglutide through similar discount channels are a separate category.
Read our full Cost Plus Drugs review →Pros & Cons
bmiMD
What we like
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $139 a month, 48% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Cost Plus Drugs
What we like
- Semaglutide at $279 a month, 79% below the $1299 median for the same drug and form across this register
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
Our Verdict
bmiMD takes it, 9.1 against 6.5, and it is especially strong on starting below a standard dose, with microdose tiers. Cost Plus Drugs is no weak second and may fit you better on coverage in all 50 states, which most of the register will not confirm.
Choose bmiMD if…
You want starting below a standard dose, with microdose tiers and an opening price near $99 a month.
Choose Cost Plus Drugs if…
You want coverage in all 50 states, which most of the register will not confirm and an opening price near $279 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Telos Rx
Starting below a standard dose, with microdose tiers
From $49/mo
Get started →MyDrHank
An oral route if you will not self-inject
From $25/mo
Get started →SkinnyRx
Starting below a standard dose, with microdose tiers
From $149.25/mo
Get started →bmiMD vs Cost Plus Drugs: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring bmiMD and Cost Plus Drugs head-to-heads in the same category.
- bmiMD vs Trimi Health
- bmiMD vs Embody
- bmiMD vs He & She MD
- Cost Plus Drugs vs Lean Meds
- Cost Plus Drugs vs NextMeds
- Cost Plus Drugs vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.